奧翔藥業(603229.SH)：與Stada Arzneimittel AG簽訂產品開發和商業化臨時合作協議
格隆匯 3 月 26日丨奧翔藥業(603229.SH)公佈，公司於2021年3月26日與Stada Arzneimittel AG (“Stada”)簽訂了《產品開發和商業化臨時合作協議》，在公司完成特定品種原料藥開發目標以及實現雙方約定的成果後，Stada將按研發進度和研發成果分四次支付給公司特定品種原料藥開發預計約1000萬歐元的研發款項。
項目內容：Stada和奧翔希望利用各自專業知識和研發能力在產品開發和商業化方面進行合作，以形成相應的開發成果(包括但不限於工藝技術包、藥品註冊文件及相關知識產權等)。
雙方基於多年合作建立的互信以及基於對時間窗口重要性的共識，為了避免為簽訂正式協議的談判耗時過長導致錯過產品開發及未來上市的重要時間窗口，雙方決定先行簽訂這一臨時協議，以推動雙方合作的儘早啟動。
Stada作為一個擁有百年淵源的全球化藥企，在全球30個國家擁有50個分支機構，銷售網絡遍佈全球。Stada擁有上百個製藥配方，具有非常豐富的非專利藥的研發、生產、銷售經驗。公司通過與Stada的此次合作，有助於公司迅速擴充產品線種類，進一步提升自身研發實力，擴大銷售市場和全球影響力，對公司的戰略實施和長遠發展將產生積極而深遠的影響。
Stada預計將在2021年至2022年按研發進度和研發成果分四次支付給公司特定品種原料藥開發的研發款項，若公司未來能與Stada簽訂正式協議且順利完成相關研發工作並實現雙方約定的成果後，則Stada支付給公司的研發款項將按《企業會計準則》中的收入準則計入相關年度的損益，對公司相關年度的業績將產生積極影響。若公司未能按計劃如期完成或觸發退款條件，則公司將無法獲得Stada向公司支付的全部研發款項，屆時公司將按雙方約定的算法部分或全部歸還Stada向公司支付的相關研發款項，公司將不能確認部分或者全部收入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
